Sareum Holdings PLC SRA737 update (8283H)
06 August 2021 - 4:19PM
UK Regulatory
TIDMSAR
RNS Number : 8283H
Sareum Holdings PLC
06 August 2021
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Reference to Potential SRA737 Opportunity in Sierra Oncology
Investor Call
Cambridge, UK, 6 August 2021 - Sareum Holdings plc (AIM: SAR),
the specialist drug development company, notes that Sierra
Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor),
held an investor call last night at 10pm BST to discuss its newly
announced global in-licensing agreement with AstraZeneca for
AZD5153, a novel BRD4 BET inhibitor, to expand its myelofibrosis
pipeline.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed to Sierra in September 2016.
In discussing the rationale for adding AZD5153 to its pipeline,
Sierra referred to possible pipeline expansion opportunities in
other haematologic or solid tumour indications, through potential
combinations with SRA737, immune-oncology agents, PARP inhibitors
and drugs with other mechanisms of action.
Sierra also noted that AZD5153 had shown preclinical efficacy in
combination with a diverse range of agents, and that synergy
between AZD5153 and a family of DNA damage response agents, known
as ATR inhibitors, suggested potential utility in combination with
SRA737.
In its 10-K filing, published yesterday, Sierra reiterated that
it is focusing its resources on the development of momelotinib and
exploring options to potentially support the continued development
of SRA737.
Sareum's CEO, Dr Tim Mitchell, commented :
"It is encouraging to note from Sierra's investor call that,
while it has made no commitment towards the further development of
SRA737, it sees further potential opportunities for this novel
agent following the addition of AZD5153 into its pipeline. We
remain optimistic that Sierra will find a solution to advance
development of the SRA737 programme in the future."
A recording of Sierra Oncology's investor call can be found at
www.sierraoncology.com
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated
Adviser)
James Dance / James Bellman 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
MEDiSTRAVA Consulting (Financial
PR)
Mark Swallow / David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the 'cytokine storm' immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
continues to explore options that would enable the development of
SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKABDABKKOFK
(END) Dow Jones Newswires
August 06, 2021 02:19 ET (06:19 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024